ArticleBMC medicine2025
Suppression of 6-pyruvoyl-tetrahydropterin synthase promotes remyelination in multiple sclerosis.
Article in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundMultiple sclerosis (MS) is a CNS autoimmune disease that is characterized by demyelination, neuroinflammation, and neuronal loss. Although current chemotherapies and immunotherapies for MS efficiently mitigate disease activity and relief clinical symptoms, neuroprotection targeting axon/neurons remains therapeutically challenging. Accumulating evidence has suggested that poor oligodendrocyte precursor cell (OPC) proliferation and subsequent migration/differentiation significantly impedes remyelination during MS. However, the molecular mechanisms underlying OPC dysfunction during MS remain elusive.
methodsRe-analysis of single-cell sequencing data from human and mouse oligodendrocyte lineage cells (OLCs), along with staining results from brain sections of MS patients, was conducted to investigate the role of 6-pyruvoyl-tetrahydropterin synthase (PTS) in determining oligodendrocyte fate. To assess PTS function in MS, conditional knockout mice targeting OLCs were employed. Transcriptomic analyses further illuminated the molecular mechanisms through which PTS influences the disease process.
resultsPTS in OPC is a suppressor of OPC proliferation that contributes to demyelination in MS. We found that PTS expression in OPC was aberrantly increased in patients with MS. Mice lacking Pts specifically in OPC displayed ameliorated experimental autoimmune encephalitis (EAE) severity, a mouse model of MS, which were accompanied by attenuated demyelination. Moreover, selective suppression of Pts in OPC facilitated OPC proliferation and remyelination during EAE. Mechanistically, the knockdown of Pts activated the cholesterol biosynthesis pathway leading to enhanced OPC proliferation.
conclusionsOur findings suggest that PTS is a negative regulator of OPC proliferation, and its disinhibition could offer a potential therapeutic target for MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.